Table of Content



1. Introduction To The Report

2. Dry Age-Related Macular Degeneration: Summary

3. Overview
3.1. Introduction
3.2. Symptoms
3.3. Risk Factors
3.4. Pathogenesis
3.5. Etiology
3.6. Diagnosis
3.7. Treatment

4. Market Dynamics
4.1. Key Drivers
4.1.1. Strong Development Pipeline For Dry Amd Treatments
4.1.2. Increasing Geriatric Population And Rising Prevalence Of Age-Related Macular Degeneration (Amd)
4.1.3. Supportive Medicare Policies For Amd Management
4.2. Key Restraints
4.2.1. Challenges In Early Detection
4.2.2. Unsuccessful Clinical Trial Results
4.2.3. Shortage Of Approved Treatments

5. Pipeline Therapeutics
5.1. Pipeline Scenario
5.2. Comparative Analysis: Products In Various Phases

6. Therapeutic Assessment: Active Products
6.1. Evaluation By Route Of Administration
6.2. Evaluation By Stage And Route Of Administration
6.3. Evaluation By Molecule Type
6.4. Evaluation By Stage And Molecule Type
6.5. Evaluation By Product Type
6.6. Evaluation By Stage And Product Type

7. Early-Stage Products (Phase I/Ii)
7.1. Comparative Analysis
7.2. Voy-101: Perceive Biotherapeutics Inc
7.2.1. Product Description
7.2.2. Research And Development
7.2.3. Product Developmental Activities
7.3. Ocu410: Ocugen
7.3.1. Product Description
7.3.2. Research And Development
7.3.3. Product Developmental Activities
7.4. Rpesc-Rpe-4W: Luxa Biotechnology
7.4.1. Product Description
7.4.2. Research And Development
7.4.3. Product Developmental Activities
7.5. Ma09-Hrpe (Asp7317): Astellas Pharma
7.5.1. Product Description
7.5.2. Research And Development
7.6. Cpcb-Rpe1: Regenerative Patch Technologies
7.6.1. Product Description
7.6.2. Research And Development
7.6.3. Safety And Efficacy

8. Early-Stage Products (Phase I)
8.1. Comparative Analysis
8.2. Ro7303359: Hoffmann-La Roche
8.2.1. Product Description
8.2.2. Research And Development
8.3. Olx301A: Olix Pharmaceuticals
8.3.1. Product Description
8.3.2. Research And Development
8.3.3. Product Developmental Activities
8.4. Bi 771716: Boehringer Ingelheim
8.4.1. Product Description
8.4.2. Research And Development
8.4.3. Product Developmental Activities
8.5. Onl 1204: Onl Therapeutics
8.5.1. Product Description
8.5.2. Research And Development
8.5.3. Product Developmental Activities
8.6. Remofuscin: Katairo
8.6.1. Product Description

9. Strategic Developments
9.1. Partnerships & Agreements

10. Unmet Needs



List of Figures

List Of Figures
Figure 1: Neovascularization And Drusen Formation
Figure 2: Symptoms Associated With Dry Age-Related Macular Degeneration
Figure 3: Schematic Diagram Of Amd Genetics Related Genes/Proteins
Figure 4: Fundus Photography And Sd-Oct Images Of Early (A) And Late Cases (B) Of Dry Amd
Figure 5: Treatment Algorithm For Amd
Figure 6: Schematic Diagram Of Cell Therapy And Gene Therapy For Amd
Figure 7: Products In Various Phases
Figure 8: Evaluation By Route Of Administration
Figure 9: Evaluation By Stage And Route Of Administration
Figure 10: Evaluation By Molecule Type
Figure 11: Evaluation By Stage And Molecule Type
Figure 12: Evaluation By Product Type
Figure 13: Evaluation By Stage And Product Type

List of Tables

LIST OF TABLES
TABLE 1: TOTAL ACTIVE PRODUCTS IN DRY AGE-RELATED MACULAR DEGENERATION PIPELINE
TABLE 2: PRODUCTS IN VARIOUS PHASES
TABLE 3: EVALUATION BY ROUTE OF ADMINISTRATION
TABLE 4: EVALUATION BY MOLECULE TYPE
TABLE 5: EVALUATION BY PRODUCT TYPE
TABLE 6: EARLY-STAGE PRODUCTS (PHASE I/II)
TABLE 7: CLINICAL TRIALS DESCRIPTION: VOY-101
TABLE 8: GENERAL DESCRIPTION: VOY-101
TABLE 9: CLINICAL TRIALS DESCRIPTION: OCU410
TABLE 10: GENERAL DESCRIPTION: OCU410
TABLE 11: CLINICAL TRIALS DESCRIPTION: RPESC-RPE-4W
TABLE 12: GENERAL DESCRIPTION: RPESC-RPE-4W
TABLE 13: CLINICAL TRIALS DESCRIPTION: MA09-HRPE
TABLE 14: GENERAL DESCRIPTION: MA09-HRPE
TABLE 15: CLINICAL TRIALS DESCRIPTION: CPCB-RPE1
TABLE 16: GENERAL DESCRIPTION: CPCB-RPE1
TABLE 17: EARLY-STAGE PRODUCTS (PHASE I)
TABLE 18: CLINICAL TRIALS DESCRIPTION: RO7303359
TABLE 19: GENERAL DESCRIPTION: RO7303359
TABLE 20: CLINICAL TRIALS DESCRIPTION: OLX10212
TABLE 21: GENERAL DESCRIPTION: OLX301A
TABLE 22: CLINICAL TRIALS DESCRIPTION: BI 771716
TABLE 23: GENERAL DESCRIPTION: BI 771716
TABLE 24: CLINICAL TRIALS DESCRIPTION: ONL1204
TABLE 25: GENERAL DESCRIPTION: ONL1204
TABLE 26: GENERAL DESCRIPTION: REMOFUSCIN
TABLE 27: LIST OF PARTNERSHIPS & AGREEMENTS